• RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more DMARDs1
  • Approval was based on the open-label Phase 1 SELECT-YOUTH study and data from adults with rheumatoid arthritis1,2
  • A new oral solution of RINVOQ was approved for use in patients with pJIA1
  • RINVOQ is currently approved in the European Union for 11 indications across various immune-mediated, inflammatory diseases1